title: Bendamustine therapy associated resolution of anemia and splenomegaly in myelofibrosis.
authors.affiliation: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
authors.affiliation: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
authors.forename: Sonia
authors.initials: S
authors.lastname: Cerquozzi
authors.affiliation: Hematologist-Oncologist, Bayside, New York.
authors.forename: Jenny
authors.initials: J
authors.lastname: Liaw
mesh_terms: D000740:Anemia / Q000150:complications / Q000188:drug therapy*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013163:Splenomegaly / Q000150:complications / Q000188:drug therapy*; D013920:Thrombocythemia, Essential / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000069461:Bendamustine Hydrochloride